|
|
IMP321 |
|
Vaxjo ID |
214 |
|
Vaccine Adjuvant Name |
IMP321 |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
CTB (Cholera toxin subunit B) can be used as a genetic adjuvant to enhance systemic immune responses and as a potent adjuvant to improve both systemic and mucosal T-cell responses. |
|
Stage of Development |
Clinical Trial |
|
Components |
IMP321 (LAG-3Ig fusion protein) |
|
Structure |
LAG-3Ig fusion protein |
|
Dosage |
25 micrograms initially, upped to 250 in absence of toxic side effects |
|
Function |
Vaccination with IMP321 as an adjuvant in combination with lymphodepleting chemotherapy and adoptive transfer of autologous PBMCs induced more robust and durable cellular antitumor immune responses, supporting further development of IMP321 as an adjuvant for future immunotherapeutic strategies. |
|
Safety |
The abstract does not provide a dedicated section on safety findings or adverse events. |
| Related Vaccine(s) |
|
| References |
Romano et al., 2014: Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A, Romero P, Speiser DE, Triebel F, Leyvraz S, Harari A. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. Journal of translational medicine. 2014; 12; 97. [PubMed: 24726012].
|
|
